DERM has been the subject of several other reports. Zacks Investment Research lowered Dermira from a hold rating to a sell rating in a report on Thursday, March 8th. Mizuho reiterated a buy rating on shares of Dermira in a report on Friday, February 23rd. Cantor Fitzgerald set a $45.00 price target on Dermira and gave the company a buy rating in a report on Monday, January 15th. Guggenheim lowered Dermira from a buy rating to a neutral rating in a report on Tuesday, March 6th. Finally, BidaskClub lowered Dermira from a buy rating to a hold rating in a report on Monday, February 5th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $32.71.
Shares of Dermira stock opened at $8.33 on Thursday. The stock has a market capitalization of $365.52, a PE ratio of -1.13 and a beta of 0.86. The company has a debt-to-equity ratio of 1.87, a quick ratio of 5.28 and a current ratio of 5.28. Dermira has a 1-year low of $8.33 and a 1-year high of $36.21.
In related news, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $28.55, for a total value of $85,650.00. Following the completion of the sale, the insider now directly owns 5,802 shares in the company, valued at approximately $165,647.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total value of $499,288.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,758 shares of company stock valued at $728,459. Corporate insiders own 13.30% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of DERM. Millennium Management LLC bought a new position in Dermira in the 4th quarter worth approximately $25,084,000. Franklin Resources Inc. bought a new position in Dermira in the 4th quarter worth approximately $24,820,000. Point72 Asset Management L.P. increased its position in Dermira by 621.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock worth $19,248,000 after buying an additional 614,138 shares during the period. Emerald Advisers Inc. PA bought a new position in Dermira in the 4th quarter worth approximately $14,918,000. Finally, Dimensional Fund Advisors LP bought a new position in Dermira in the 3rd quarter worth approximately $3,107,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.